IL-17C:一种独特的上皮细胞因子,有望靶向治疗特应性皮炎和银屑病谱系疾病
特应性皮炎和银屑病均存在表皮「前馈」炎症环路,角质形成细胞产生的IL-17C参与放大两者的炎症反应。拮抗IL-17C可能对两种疾病均有益,中和抗体MOR 106可抑制驱动两者不同特征的Th2和Th17/Th22炎症环路。近期一项针对特应性皮炎患者的小型1期临床试验支持IL-17C拮抗在特应性皮炎中的治疗潜力。
要点
- IL-17C由角质形成细胞产生,参与放大特应性皮炎和银屑病炎症的协同环路。
- 拮抗IL-17C可能对银屑病和特应性皮炎患者均有益。
- IL-17C中和抗体MOR 106可抑制Th2及Th17/Th22偏倚的炎症环路。
核心结论
- 拮抗IL-17C可能对银屑病和特应性皮炎患者均有益。
研究设计与样本
- 原文为综述,未报告系统检索范围。
主要发现
- IL-17C是由角质形成细胞产生的独特细胞因子,参与可能放大两种疾病炎症的协同环路,并最终诱导S100A及其他伴随表皮增生的分子。
- IL-17C中和抗体MOR 106能够抑制驱动特应性皮炎和银屑病不同特征的Th2细胞和Th17/Th22偏倚炎症环路。
关键数值与推荐
- 近期报告的一项针对特应性皮炎患者的小型1期临床试验支持IL-17C拮抗在特应性皮炎中的治疗潜力。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Both atopic dermatitis (AD) and psoriasis are characterized by complex inflammatory circuits that may be regulated through "feed-forward" mechanisms in the epidermis that amplify cellular immune responses through production of keratinocyte-derived cytokines and inflammatory mediators. IL-17C is a unique cytokine that is produced by keratinocytes and that is involved in such synergistic loops that may be responsible for amplifying the inflammation in both diseases. This may ultimately lead to induction of S100As and other molecules that accompany epidermal hyperplasia. Thus, antagonism of IL-17C may be beneficial in both psoriasis and AD patients. The IL-17C neutralizing antibody MOR 106 was able to inhibit both T helper type 2 cells and T helper type 17/T helper type 22-skewed inflammatory loops that drive different features of AD and psoriasis. The therapeutic potential of IL-17C antagonism in AD is supported by a recently reported small phase 1 clinical trial in patients with AD.
引用
- Guttman-Yassky E, Krueger JG. IL-17C: A Unique Epithelial Cytokine with Potential for Targeting across the Spectrum of Atopic Dermatitis and Psoriasis. J Invest Dermatol. 2018. PMID: 29941097. doi:10.1016/j.jid.2018.02.037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。